Catalog No.
Product Name
Application
Product Information
Citations
-
FKBP ligand
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules. - Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
- GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.
- Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.
-
androgen ligand
Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to cIAP1 ligand Bestatin via a linker to form PROTACs. -
estrogen ligand
Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER. - ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells.
-
Sirt2 inhibitor
SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC50 of 2.4 μM. -
FKBP ligand
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs. - PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors.
- N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.
- PROTAC BRD9-binding moiety 1 is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.
-
BRD4 inhibitor
I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC50 of 5.1. - Desmethyl-QCA276, the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC50 of 10 nM, and with a Ki of 2.3 nM.
- SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
-
BET bromodomain inhibitor
PROTAC BET-binding moiety 2 is an inhibitor of BET bromodomain. -
SOS1 activator
VUBI1 (SOS1 Activator 1) is a benzimidazole-derived small molecule that acts as a potent activator of the guanine nucleotide exchange factor SOS1, with a dissociation constant (Kᴅ) of 44 nM. It promotes RAS activation by enhancing RAS-GTP formation and modulates downstream ERK phosphorylation, thereby influencing RAS–MAPK signaling. In addition, VUBI1 serves as a functional ligand for the development of PROTAC-based degraders, such as PROTAC SOS1 Degrader-1, to induce targeted SOS1 degradation. VUBI1 is a valuable compound for studying RAS pathway regulation and its role in cancer biology. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH is a ligand specifically designed for EZH2, functioning as a key component in PROTAC technology by recruiting E3 ligases. This compound demonstrates potential biological activity in targeted protein degradation, particularly in the context of lymphoma research. Its unique structure allows for the exploration of novel therapeutic strategies aimed at modulating EZH2 activity and its downstream effects in cancer biology. -
Ligands for Target Protein for PROTAC
CBP/p300 ligand 10 is a selective ligand for the CBP/p300 proteins, facilitating their targeted degradation. This compound serves as a valuable component for the development of PROTACs, specifically enabling the synthesis of CBP/p300 Degrader-2. Its utility in research applications includes studies focused on cellular signaling pathways and potential therapeutic interventions in diseases associated with dysregulated CBP/p300 activity. -
Ligands for Target Protein for PROTAC
(Rac)-BMS-1 is a racemic compound that serves as a ligand for target proteins in the development of proteolysis-targeting chimeras (PROTACs). It plays a crucial role in synthesizing D5B PROTAC, facilitating targeted protein degradation. This compound is valuable for researchers investigating protein regulation and therapeutic applications in cancer and other diseases. -
Ligands for Target Protein for PROTAC
SHP2-IN-43 is a potent inhibitor of SHP2, demonstrating an IC50 of 98.7 nM. This compound serves as a valuable ligand for targeted protein degradation (PROTAC) applications, facilitating the synthesis of SHP2-D26. Researchers can utilize SHP2-IN-43 to explore the therapeutic potential of modulating SHP2 activity in various biological contexts. -
Ligands for Target Protein for PROTAC
GNF-8625 is a potent TRK inhibitor that functions by targeting TRK receptor tyrosine kinases, specifically TRKA, TRKB, and TRKC, with IC50 values of 0.8 nM, 22 nM, and 5.4 nM, respectively. This compound can be utilized in conjunction with Thalidomide to create a PROTAC degrader, enabling targeted protein degradation. GNF-8625 is valuable in research applications investigating TRK-mediated pathways and offers potential in therapeutic strategies for cancers involving aberrant TRK signaling. -
Ligands for Target Protein for PROTAC
BTK ligand 12 is a potent ligand for Bruton's tyrosine kinase (BTK), functioning as a valuable component in the development of PROTACs targeting this protein. It exhibits strong binding affinity, facilitating the effective ubiquitination and degradation of BTK in various cellular contexts. This compound is essential for researchers investigating targeted protein degradation and the modulation of signaling pathways associated with BTK in therapeutic applications. -
BTK/IKZF1/3 PROTAC Ligand
BTK/IKZF1/3 ligand 1 is a PROTAC ligand targeting Bruton's tyrosine kinase (BTK) and the Ikaros family zinc finger proteins (IKZF1/3). This compound can be conjugated with E3 ligase ligands and linkers to produce PROTAC BTK/IKZF1/3 Degrader-1, facilitating targeted protein degradation. It is valuable for cancer research, supporting investigations into therapeutic strategies aimed at modulating BTK and IKZF1/3 activity in malignant cells. -
Ligands for Target Protein for PROTAC
ALK protein ligand-1 is a specific ligand for anaplastic lymphoma kinase (ALK) that plays a crucial role in targeted protein degradation using PROTAC technology. This compound exhibits potent inhibitory effects on ALK, making it a valuable tool for studying ALK-related signaling pathways and their implications in cancer biology. ALK protein ligand-1 is essential for the synthesis of AP-1, facilitating the exploration of novel therapeutic approaches in oncology research. -
Ligands for Target Protein for PROTAC Chemical
PROTAC BRD4 ligand-2 is a specific ligand for the BRD4 protein, designed for use in PROTAC-mediated degradation strategies. This compound facilitates the targeted degradation of BRD4, a key regulator of transcription and associated with various cancers, by recruiting the E3 ubiquitin ligase. It is instrumental in research applications aimed at understanding BRD4's role in oncogenesis and therapeutic development in cancer treatments. -
SMARCA2/4 Ligand
SMARCA2/4-ligand-5 is a selective ligand targeting the SMARCA2 and SMARCA4 proteins, functioning as a crucial component in the PROTAC SMARCA2/4 degrader-37. This compound demonstrates potent biological activity, achieving an IC50 of ≤0.1 μM, making it suitable for applications in targeted protein degradation studies. Research utilizing SMARCA2/4-ligand-5 contributes to understanding the roles of these chromatin remodelers in various biological processes and cancer biology. -
Ligand of BRAF
BRAF ligand-1 acts as a specific ligand for the BRAF protein, playing a crucial role in the regulation of cell signaling pathways associated with cell proliferation, survival, and differentiation. This compound is important for studying the BRAF signaling pathway and its implications in various cancers. Additionally, BRAF ligand-1 can be utilized in the synthesis of CST905, further enhancing its utility in biochemical research and drug discovery efforts targeting mutant BRAF. -
Ligands for Target Protein for PROTAC
FN-1501-propionic acid is a ligand targeting cyclin-dependent kinases 2 and 9 (CDK2/9), utilized in the development of PROTAC (proteolysis targeting chimeras) for targeted protein degradation. This compound can be combined with a CRBN ligand to facilitate the design of PROTAC-based CDK2/9 degraders, enabling selective degradation of these kinases. Its application in research enhances the study of cellular processes regulated by CDK2 and CDK9, making it a valuable tool for investigating therapeutic strategies against diseases associated with dysregulated kinase activity. -
CDK9 Degrader/Ligands for Target Protein for PROTAC
(R)-PROTAC CDK9 ligand-1 is a potent degrader targeting cyclin-dependent kinase 9 (CDK9), a key regulator of transcription and cell cycle progression. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), which exhibit antitumor activity by promoting the degradation of CDK9. Research applications include investigations into cancer biology and therapeutic strategies aimed at modulating CDK9 levels for improved treatment outcomes. -
Ligands for Target Protein for PROTAC
POI ligand-2 is a specific ligand for the GPX4 protein, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTACs, including PROTAC GPX4 degrader-5. Its application in protein research enables efficient modulation of GPX4 levels, aiding studies in mechanistic biology and therapeutic interventions targeting oxidative stress pathways. -
Ligands for Target Protein for PROTAC
Androgen Receptor Ligand 2 acts as a ligand for the androgen receptor, facilitating the targeted degradation of this protein through the PROTAC (proteolysis-targeting chimera) mechanism. This compound is integral for the synthesis of the PROTAC Androgen Receptor Degrader-1, enabling researchers to probe the functional role of the androgen receptor in various biological contexts. Its application extends to studies in cancer research and hormone-related disorders, where modulation of androgen receptor activity may serve as a therapeutic strategy. -
Ligands for Target Protein for PROTAC
SMARCA-BD ligand 1 for PROTAC hydrochloride is a selective ligand that specifically targets the BAF ATPase subunit SMARCA2. This compound facilitates the degradation of SMARCA2 through the PROTAC mechanism, making it a valuable tool for research into protein degradation pathways and epigenetic regulation. Its applications extend to studies on cancer biology and the development of targeted therapeutic strategies. -
Ligands for Target Protein for PROTAC
SMARCA-BD ligand 1 for PROTAC dihydrochloride is a selective ligand targeting the BAF ATPase subunit SMARCA2. This compound facilitates the proteolytic degradation of SMARCA2 through the PROTAC mechanism, thereby modulating its biological activity. It is utilized in research applications focused on the regulation of chromatin remodeling and exploring therapeutic avenues for diseases associated with altered SMARCA2 function. -
SMARCA2 Ligand
SMARCA2 ligand-11 is a specific ligand for the chromatin remodeling factor SMARCA2, facilitating the development of PROTACs such as SMARCA2 degrader-32. This compound is instrumental in research applications focused on targeted protein degradation, particularly in studies aimed at elucidating the role of SMARCA2 in various biological processes and diseases. Its ability to selectively engage with SMARCA2 allows for investigations into novel therapeutic strategies in cancer and other conditions where SMARCA2 activity is implicated. -
Intermediate
7α,25-Dihydroxycholesterol intermediate-1 is a crucial synthetic intermediate in the production of 7α,25-Dihydroxycholesterol. This compound functions as a ligand for the orphan G protein-coupled receptor EBI2 (GPR183), playing a significant role in immune system regulation and cellular signaling pathways. Its applications extend to the development of PROTACs, enabling targeted protein degradation in research and therapeutic contexts. -
Ligands for Target Protein for PROTAC
PD0325901-O-C2-dioxolane is a derivative of the MEK inhibitor PD0325901, designed as a ligand for targeted protein degradation in conjunction with VHL or CRBN E3 ligases. This compound facilitates the synthesis of MEK1/2 degraders, enabling the selective degradation of MEK proteins in experimental studies. Its application in research provides critical insights into MEK-related signaling pathways and their role in various diseases, particularly in cancer biology. -
Ligand for Target Protein for PROTAC
PROTAC SOS1 ligand 1 is a high-affinity ligand for the SOS1 protein, facilitating targeted protein degradation through PROTAC technology. This compound is instrumental in the development of therapeutic strategies by enabling the selective modulation of SOS1, which plays a pivotal role in various oncogenic signaling pathways. Researchers can utilize this reagent in studies focused on cancer biology and drug discovery, particularly in exploring novel approaches to target and degrade specific proteins associated with tumor progression. -
Ligands for Target Protein for PROTAC
Thalidomide-5-piperazine is a ligand designed for protein-targeted degradation utilizing the PROTAC technology. This compound facilitates the recruitment of E3 ubiquitin ligases to specific target proteins, promoting their ubiquitination and subsequent proteasomal degradation. It is primarily used in research applications focused on studying protein function and modulation within cellular pathways. -
Ligands for Target Protein for PROTAC
Palbociclib-propargyl is a selective ligand for CDK6, designed for use in PROTAC applications. This compound functions through a PEG linker to effectively bind to the CRBN ligand, forming the PROTAC CP-10, which exhibits a DC50 of 2.1 nM for CDK6. Additionally, Palbociclib-propargyl features an alkyne group making it suitable for click chemistry, specifically allowing for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-bearing molecules. This reagent is valuable for advancing research in targeted protein degradation and cancer therapeutics. -
Ligands for Target Protein for PROTAC
(S)-SKBG-1 is a covalent ligand designed for targeting specific proteins in the context of PROTAC applications. Though classified as inactive, it serves an essential role as an assay control to help validate experimental conditions and results. This compound is valuable for researchers investigating the mechanisms of protein degradation and the development of targeted therapeutic strategies. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methyl morpholine)-COOH is a ligand specifically designed for the target protein EZH2, facilitating the synthesis of EZH2 degraders for the PROTAC approach. This compound exhibits significant biological activity by effectively inhibiting cell viability in diffuse large B-cell lymphoma (DLBCL) and various lymphoma subtypes. It serves as a valuable tool for researchers investigating targeted protein degradation and its therapeutic potential in oncology. -
Ligands for Target Protein for PROTAC
PROTAC BRD9-binding moiety 1 hydrochloride is a ligand that selectively binds to the bromodomain protein BRD9, facilitating its targeted degradation through the PROTAC (Proteolysis Targeting Chimeras) mechanism. This compound is instrumental in research focusing on protein degradation pathways and the modulation of BRD9-associated functions in various biological contexts, such as cancer and inflammation. It serves as a valuable tool for studying the therapeutic potential of targeting BRD9 in disease models. -
Ligands for Target Protein for PROTAC
Piperidine-GNE-049-N-Boc is a ligand that targets the dCBP-1 protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound serves as a potent and selective heterobifunctional degrader for the transcriptional co-activators p300 and CBP. It is applicable in research aimed at understanding protein degradation mechanisms and the modulation of gene expression. -
Ligands for Target Protein for PROTAC
Demethyl-RSL3 functions as a ligand for targeted protein degradation through the proteolysis targeting chimera (PROTAC) mechanism. This compound effectively modulates cellular pathways by inducing degradation of specific proteins. Its applications lie primarily in cancer research and the development of novel therapeutic strategies aimed at improving targeted protein degradation efficacy. -
Ligands for Target Protein for PROTAC Chemical
PROTAC CDK9 ligand-1 is a potent ligand for cyclin-dependent kinase 9 (CDK9), facilitating the synthesis of PROTAC (proteolysis-targeting chimera) constructs. This compound is instrumental for targeted protein degradation studies, enabling researchers to modulate CDK9 activity and investigate its role in transcription regulation and cancer biology. PROTAC CDK9 ligand-1 supports the development of innovative therapeutic strategies aimed at selectively degrading unwanted or malfunctioning proteins. -
Ligands for Target Protein for PROTACs
PRMT5 ligand 2 is a selective ligand targeting protein arginine methyltransferase 5 (PRMT5) for use in PROTAC (proteolysis-targeting chimeras) applications. This compound facilitates the targeted degradation of PRMT5, enabling researchers to investigate its role in various cellular processes, including gene regulation and cell signaling. PRMT5 ligand 2 serves as an essential tool for studying PRMT5's biological functions and elucidating potential therapeutic targets in cancer and other diseases.
